C
Cascade Medical Research Institute, LLC | Springfield, OR
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
KSI-301
Aflibercept
JNJ-81201887
Tarcocimab
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 5 total trials
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.
Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems